Evidence map›Paper›PMID 24753747›Full record

ArticleInternational journal of clinical and experimental medicine2014

Effects of APP 5-mer peptide analogue P165 on the synaptic proteins and insulin signal transduction proteins.

Bo Feng, Peng Hu, Shu-Jun Lu, Rong Wang, Yi-Feng Du

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bo FengDepartment of Neurology, Provincial Hospital Affiliated to Shandong University 324 Jingwu Road, Jinan, Shandong 250021, China ; Department of Neurology, Hospital Affiliated to Binzhou Medical University 661 Second Huanghe Street, Binzhou 256603, China ; Department of Spine, Hospital Affiliated to Binzhou Medical University 661 Second Huanghe Street, Binzhou 256603, China.
Peng HuDepartment of Spine, Hospital Affiliated to Binzhou Medical University 661 Second Huanghe Street, Binzhou 256603, China.
Shu-Jun LuDepartment of Neurology, Hospital Affiliated to Binzhou Medical University 661 Second Huanghe Street, Binzhou 256603, China.
Rong WangCentral Laboratory, Xuanwu Hospital, Capital Medical University 45 Changchun Street, Beijing 100053, China.
Yi-Feng DuDepartment of Neurology, Provincial Hospital Affiliated to Shandong University 324 Jingwu Road, Jinan, Shandong 250021, China.
Binzhou University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic encephalopathy (DE) is one of risk factors for Alzheimer's disease (AD). Our previous findings indicated that DE animals had impairment of learning and memory and degeneration of hippocampal neurons, which could be improved by neurotrophic peptide. APP 17-mer peptide is a synthesized peptide sequenced from soluble amyloid precursor protein. APP 17-mer peptide has neural protective effect, but is susceptible to enzyme degradation. Soluble APP 5-mer peptide is the active form of APP 17-mer peptide, and composed of arginine, glutamic acid, arginine, methionine and serine. P165, an APP 5-mer peptide analog reconstructed by our lab, is resistant to enzyme degradation, and can be orally used to protect neurons. In the present study, high glucose and Aβ25-35 were used to cause injury to human neuroblastoma cell line SH-SY5Y in vitro, and streptozotocin was used to induce diabetes in mice in vivo. The changes in synaptic proteins and proteins of insulin signal transduction which closely correlate with learning and memory were detected in these cells and the brain of mice. Results showed that P165 could up-regulate the expression of α-synuclein and insulin receptor (IR), down-regulate the expression of insulin receptor substrate-1 (IRS-1), PSD-95, Shank1 and MAPK expression. All these findings suggest that nicorandil might be a potential drug used for the treatment of AD.

Indexed as

Alzheimer’s diseaseAPP 5-mer peptide analogue P165diabetes mellitusinsulin signal transductionsynapse

Identifiers

PMID24753747
PMCPMC3992392
OpenAlexW2265346152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.